Dr. Garissino on Combinations With Immune Checkpoint Inhibitors in NSCLC

Name: Dr. Garissino on Combinations With Immune Checkpoint Inhibitors in NSCLC
Uploaded: 2017-10-31T20:06:00.000Z
Description: Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses combinations with immune checkpoint inhibitors in non-small cell lung cancer.

October 31, 2017

Marina Chiara Garassino, MD

Video

Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses combinations with immune checkpoint inhibitors in non-small cell lung cancer.

Garassino says that the future of immunotherapy in NSCLC lies in combinations.

In the future, treatment will be based on phenotype, says Garissino. The 3 phenotypes that are known right now in NSCLC are inflamed and immune-excluded, and immune-desert.